Loading clinical trials...

COMPLETED

Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population

NCT06763887•Xijing Hospital

Summary

The purpose of this study is to evaluate the immunogenicity and immune protection of COVID-19, especially the recently prevalent strains, against the background of current immunization in Chinese population

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. He was infected with COVID-19 from November to December 2022;
•2. Have not been infected with COVID-19 (the subject said that he was not infected and signed the informed consent form);
•3. Those who agree and sign the informed consent form.

Exclusion Criteria

•1. Missing or incomplete questionnaires that affect research results;
•2. Individuals with combined dysfunction of important organs such as the heart, liver, and lungs;
•3. Mental and behavioral abnormalities;
•4. Intellectual disability;
•5. Under 18 years old or over 75 years old;
•6. Low understanding and communication skills.

Locations (1)

The First Affiliated Hospital of Air Force Military Medical University

Xi'an, Shaanxi, China

Key Dates

Start Date

November 15, 2023

Primary Completion Date

June 30, 2024

Completion Date

June 30, 2024

Last Updated

January 8, 2025

Enrollment

100

ACTUAL participants

Conditions

COVID

Interventions

No Interventions

OTHER

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

RECRUITINGPHASE2/PHASE3

Taurine Supplementation in Long COVID

NCT06721949

Long COVID

View study

RECRUITINGPHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population

Inclusion Criteria

Exclusion Criteria

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Taurine Supplementation in Long COVID

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate